The FDA has approved a new injectable form of Eisai and Biogen's Alzheimer's drug Leqembi, enabling weekly maintenance dosing that patients can receive at home. This marks a significant regulatory advancement, addressing accessibility and convenience in Alzheimer's therapy. The approval also coincides with several rare disease drug approvals and refined FDA authorizations for Covid-19 vaccines, highlighting a dynamic period in regulatory activity. The shift to home administration may reshape care models, potentially improving patient adherence and quality of life.